Unlock new dimensions in your preclinical research
ABOUT
Facts & Figures
Neurological disorders
are a global society problem
- 7% of the population affected
- No curable neurological disease
- Yearly cost > $800 billions
Challenges of drug discovery
for neurological disorders
- 76% drug candidates fail in phase 3 after 5 to 8 years of research.
- Need to overcome in vitro models limitations to quickly identify safer and more effective drugs
SYNAXYS
A new depthto your preclinical R&D studies
Pioneer in neuro-engineering, Synaxys proposes 5D-brain. The first reliable human in vitro model of the nervous system for functional preclinical studies.
5 accessible dimensions (X, Y, Z, time, activity) to replace animal experimentation & to enhance preclinical R&D results.
- Reliable substitutes to organoids
- Measure in vivo like neuronal activity in vitro
- Mimic specific neuropathology disorders
- Enable the identification of targets, effects and regulation
Live confocal microscopy image of human neurons grown in 3D; each neuron is engineered to express a specific fluorescent protein © Synaxys
SYNAXYS
The unique properties of 5D-brains
01
ROBUST & REPRODUCIBLE
Standardized high reproducibility hIPSC differentiation processes leading to identical physiological properties
02
FAST IMPLEMENTATION
5D-brains mature 4 times faster than organoids current 3D models, and deliver reliable preclinical data in less than 3 weeks
03
MULTI-SCALENEURONAL ACTIVITY RECORDING
5D-brain is the sole 3D model capable of monitoring individual neurons’ activity over the whole network throughout all its developmental stages
SYNAXYS
Performance groundedin multidisciplinary expertise
01
TISSUE ENGINEERING
Proprietary processes to obtain in vivo like human neuronal networks in vitro
02
BIOENGINEERING TOOLS AND INSTRUMENTATION
5D-brains are in vitro models tailor made to address physiological and pharmacological questions
03
BIG DATA ANALYSIS
Global comprehensive analysis of the nervous system response to predict: target, dose effects, efficacy and regulation pathways
Services
Innovative, animal free,and cost-effective models
Description
Synaxys realizes preclinical assays and R&D projects to rapidly predict the response of the human nervous system before starting clinical trials.
Our platform offers a wide range of electrophysiological assays with supporting microscopy, genomic and proteomic data for a comprehensive analysis. Using our proprietary 5D-brain models, we propose custom pharmacology and toxicology screens on neural functions to identify the targets and actions of a compound.
Unique insight on human neurological diseases
Synaxys 5D-brain models are long lived and composed of all the neuronal cell types with their regulating elements. These intrinsic properties enable them to bring pertinent data on:
Microscopy image of a 4 week old 3D neuronal network in contact with a 60 electrodes MEA chip; axons (green), synapses (red), nuclei (blue). © Synaxys
Bursting neuronal networks, Excitatory and inhibitory activity.
Identifiable D1, D2, D3 dopamergic activity
Myelinated axons
Monitoring of neuronal networks developmental steps
Monitoring of the functional aging process
Offer:
Synaxys offers three complementary levels of services
- Pilot Tests:
Characterization of the dose response for your compounds compared to reference chemicals on a healthy mature 3D human neuronal network - Neuro-pharmocology studies:
- Identification of the biological targets of your compounds
- Determination the specific characteristics of your compounds compared to known drugs with similar targets
- Full R&D projects:
Evaluation of the therapeutic potential of a compound with 5D-brain disease models. Two models are currently available : healthy reference and epileptic model.
Modality:
Synaxys operates as a contract research organization
- Custom designed services:
We design and realize studies to evaluate and select lead compounds for your applications to provide the most exhaustive and accurate results, and we deliver a thorough confidential report directly usable for decision-making. - R&D partnerships with public or private institutions:
We participate in collaborative R&D projects as partner to answer research calls, or as coordinator to design and manage your R&D projects.
TESTIMONIALS
What they say about us
« Working with Synaxys has been very beneficial. Their breakthrough model has helped us define and back marketing arguments for our health supplements. These studies have contributed to a significant sales increase. »
« High throughput screening models that do not need fluorescent labels but report metabolic and electrical signals is greatly needed by the both scientific and pharma industry. Thus success of Synaxys’s project will have many scientific, economic impact with potential for social impact for reducing the burden of neurodegenerative disease on society. »
AGENCE NATIONALEDE LA RECHERCHE
Team
Who we are
Founders
Sophie PAUTOT
Co-founderSophie Pautot (PhD Applied Physics from Harvard, HDR) has a multi-disciplinary training and more than 15 years of experience leading high impact cross-disciplinary projects in neuroscience. She pioneered the processes that serves as scientific foundation to Synaxys 5D-brains.
Michel FARENG
Co-founderMichel Fareng (graduated from HEC) is a serial entrepreneur. For decades, he was involved in sport management, culture and education. Today he focuses on sustainable activities, environment and health issues.
Photos : Lionel Pesqué
Founders statement
We founded Synaxys because we believe that the in vivo like properties of our 5D-brains can replace animal experiments in preclinical studies and help pharmaceutical laboratories significantly improve the quality of their preclinical results to accelerate the discovery of therapeutic solution for neurological disorders.
Highlights:
- 07/2020 Synaxys welcomes a new business partner
- 06/2020 Be a Boss Occitanie award
- 05/2020 CREALIA is supporting us
- 04/2020 Initiative Haute Garonne is supporting us
- 11/2019 Invited talk at the Neurofluidics 2019 conference, Montpellier
- 10/2019 Launching of the ANR-PRCE coordinated by Synaxys
- 09/2019 Synaxys joined Eurobiomed
- 06/2019 Synaxys obtains the JEI label
- 12/2018 License agreement with the CNRS and SATT-TTT
- 03/ 2018 Kickoff of Synaxys’ activities
- 11/2017 Housing agreement with the CNRS and the ITAV
Our partners
Contact
Drop us a word
This contact form is meant to facilitate our mutual communication, and the information you enter in this form are treated as confidential. Synaxys will not share these data with third parties. Also, you can read our privacy policy, so don’t hesitate to contact us for more information.